Eugenia Shmidt, MD
Gastroenterology · Minneapolis, MNNPI 1003102989
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $140 of the $140 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Takeda Pharmaceuticals U.S.A., Inc.. That places this record below the midpoint for gastroenterology clinicians in MN, where the typical reported total is $127.
Across 3 payments — averaging $46.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$140
Across 41 payments — averaging $8684.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$300K
- UCB SA$52K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- AbbVie$2K
What the payments were for
- Speaking & faculty fees$140100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $140 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Entyvio$125
How this compares
$140 in reported general payments places this provider in the 50th percentile of 365 gastroenterology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 23 | $618,703 |
| Mesalamine | 12 | $5,402 |
| Sodium Chloride0.9 % Sodium Chloride | 43 | $2,351 |
| Balsalazide Disodium | 12 | $1,561 |
| Omeprazole | 35 | $668 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 21 | $562 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Minneapolis
- Joshua SloanMinneapolis$175K
- Stuart AmateauMinneapolis$123K
- Justin HowardMinneapolis$50K
- Guru TrikudanathanMinneapolis$46K
- Byron VaughnMinneapolis$46K
- Martin FreemanMinneapolis$32K
- Sasan MosadeghiMinneapolis$14K
- Nabeel AzeemMinneapolis$12K
- David LeungMinneapolis$12K
- John LakeMinneapolis$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.